[{"address1": "548 Market Street", "address2": "Suite 49404", "city": "San Francisco", "state": "CA", "zip": "94104", "country": "United States", "phone": "415 887 2311", "website": "https://www.bettertx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. David P. Perry M.B.A.", "age": 55, "title": "Co-Founder & Executive Chairman", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 260000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frank L. Karbe", "age": 55, "title": "CEO, Interim CFO, President & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 533369, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark A. Berman M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 573750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristin  Wynholds", "age": 51, "title": "Chief Product Officer", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 519067, "exercisedValue": 0, "unexercisedValue": 12785}, {"maxAge": 1, "name": "Mr. Andres  Camacho", "title": "Senior VP of Technology & Head of Engineering", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Diane  Gomez-Thinnes", "title": "Chief Commercial Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Angela  Willis", "title": "Senior Vice President of Market Access", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Leslie  Miller", "title": "Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.2185, "open": 0.235, "dayLow": 0.16, "dayHigh": 0.24, "regularMarketPreviousClose": 0.2185, "regularMarketOpen": 0.235, "regularMarketDayLow": 0.16, "regularMarketDayHigh": 0.24, "beta": 2.455, "forwardPE": -0.1696, "volume": 13726307, "regularMarketVolume": 13726307, "averageVolume": 1885589, "averageVolume10days": 2184300, "averageDailyVolume10Day": 2184300, "bidSize": 1200, "askSize": 800, "marketCap": 9245845, "fiftyTwoWeekLow": 0.137, "fiftyTwoWeekHigh": 1.61, "fiftyDayAverage": 0.2004, "twoHundredDayAverage": 0.486115, "currency": "USD", "enterpriseValue": 15748616, "floatShares": 21076973, "sharesOutstanding": 54515600, "sharesShort": 960686, "sharesShortPriorMonth": 1141786, "sharesShortPreviousMonthDate": 1703808000, "dateShortInterest": 1706659200, "sharesPercentSharesOut": 0.0177, "heldPercentInsiders": 0.5341, "heldPercentInstitutions": 0.02949, "shortRatio": 0.32, "shortPercentOfFloat": 0.028199999, "impliedSharesOutstanding": 54515600, "bookValue": -0.245, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -31573000, "trailingEps": -1.1, "forwardEps": -1.0, "enterpriseToEbitda": -0.54, "52WeekChange": -0.8175, "SandP52WeekChange": 0.2541988, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BTTX", "underlyingSymbol": "BTTX", "shortName": "Better Therapeutics, Inc.", "longName": "Better Therapeutics, Inc.", "firstTradeDateEpochUtc": 1615987800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "306708d6-63a5-3214-8ea5-a711d789e7e2", "messageBoardId": "finmb_598952840", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.1696, "targetHighPrice": 9.0, "targetLowPrice": 1.5, "targetMeanPrice": 5.25, "targetMedianPrice": 5.25, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 6598000, "totalCashPerShare": 0.139, "ebitda": -29175000, "totalDebt": 14307000, "quickRatio": 0.516, "currentRatio": 0.568, "returnOnAssets": -0.95052004, "freeCashflow": -15560500, "operatingCashflow": -26083000, "financialCurrency": "USD", "trailingPegRatio": null}]